India Pharma Outlook Team | Tuesday, 20 May 2025
Global pharmaceutical company Lupin, a massive firm, has announced a strategic collaboration with Honeywell to develop next-generation respiratory inhalers using Solstice Air (HFO-1234ze(E) cGMP), an innovative low-global warming potential (GWP) propellant. The new inhalers are expected to treat patients with asthma and chronic obstructive pulmonary disease (COPD) while significantly reducing environmental impact.
This move positions Lupin to become the first Indian pharmaceutical company to possibly adopt Solstice Air at scale in forced metered-dose inhalers (pMDIs). Unlike traditional hydrofluorocarbon (HFC) propellants, Solstice Air can reduce greenhouse gas production by up to 99.9 percent, offering a sustainable alternative to respiratory therapy.
While the formal agreement between Lupin and Honeywell is still under negotiation, both companies have expressed strong determination to confirm the partnership through final documentation.
Vinita Gupta, CEO of Lupin, highlighted the dual impact of the initiative, “Our partnership with Honeywell reinforces our commitment to high-quality respiratory care while actively pursuing a more sustainable and healthier future. The integration of Solstice Air into our inhalers exemplifies this dual mission.”
Ashish Modi, President of Honeywell India, stated, “Solstice Air enables the development of inhalers that not only deliver safe and effective treatment but also significantly reduce environmental harm. It represents a leap forward in respiratory care technology.”
Also Read: Aptar Empowers Indian Pharma with Inhalers, Nasal Sprays for Global Markets
He added that Honeywell remains focused on advancing health solutions through environmentally mindful innovations, assisting the pharmaceutical industry's shift toward sustainability.
With this development, Lupin is designed to lead a transformative shift in India’s respiratory drug delivery landscape to where cutting-edge treatment meets climate responsibility.
, CDSCO.jpg)
